| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2527187 | Clinical Therapeutics | 2013 | 15 Pages |
Abstract
OM3-FFA was well tolerated and lowered non-HDL-C and TG levels at both 2- and 4-g/d dosages in patients with persistent hypertriglyceridemia taking a statin, with the 4-g/d dosage providing incremental improvements compared with 2 g/d. ClinicalTrials.gov identifier: NCT01408303.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Kevin C. PhD, David G. MD, Stephen J. MBBS, PhD, Richard L. MD, Eli M. MD, FACC, Danielle MBA, Judith MT, Douglas MBA, Michael H. MD, FACC,